Crestor shines for otherwise lacklustre Shionogi
This article was originally published in Scrip
Executive Summary
The consolidation of Sciele Pharma in the US and strong growth in royalties for Crestor helped Shionogi overcome an otherwise weak underlying performance in the nine months to December 31st.